ES2639573T3 - Péptidos que tienen afinidad de unión por un anticuerpo que reconoce un epítopo en un bucle 2 de alfa 1 o bucle 1 de beta 2 de un receptor adrenérgico - Google Patents

Péptidos que tienen afinidad de unión por un anticuerpo que reconoce un epítopo en un bucle 2 de alfa 1 o bucle 1 de beta 2 de un receptor adrenérgico Download PDF

Info

Publication number
ES2639573T3
ES2639573T3 ES09702027.5T ES09702027T ES2639573T3 ES 2639573 T3 ES2639573 T3 ES 2639573T3 ES 09702027 T ES09702027 T ES 09702027T ES 2639573 T3 ES2639573 T3 ES 2639573T3
Authority
ES
Spain
Prior art keywords
deletion
nal
hph
abu
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09702027.5T
Other languages
English (en)
Spanish (es)
Inventor
Rudolf Kunze
Gerd Wallukat
Peter Rosenthal
Richard Straube
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Fresenius Medical Care Deutschland GmbH
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Fresenius Medical Care Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft, Fresenius Medical Care Deutschland GmbH filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Application granted granted Critical
Publication of ES2639573T3 publication Critical patent/ES2639573T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/281—Sorbents specially adapted for preparative, analytical or investigative chromatography
    • B01J20/286—Phases chemically bonded to a substrate, e.g. to silica or to polymers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
ES09702027.5T 2008-01-15 2009-01-15 Péptidos que tienen afinidad de unión por un anticuerpo que reconoce un epítopo en un bucle 2 de alfa 1 o bucle 1 de beta 2 de un receptor adrenérgico Active ES2639573T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08100510 2008-01-15
EP08100510A EP2080519A1 (en) 2008-01-15 2008-01-15 Peptides having binding affinity to an antibody which recognizes an epitope on an alpha1 loop 2 or beta 2 loop 1 of an adrenoreceptor
PCT/EP2009/050446 WO2009090227A2 (en) 2008-01-15 2009-01-15 PEPTIDES HAVING BINDING AFFINITY TO AN ANTIBODY WHICH RECOGNIZES AN EPITOPE ON AN α1 LOOP 2 OR β2 LOOP 1 OF AN ADRENORECEPTOR

Publications (1)

Publication Number Publication Date
ES2639573T3 true ES2639573T3 (es) 2017-10-27

Family

ID=39402559

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09702027.5T Active ES2639573T3 (es) 2008-01-15 2009-01-15 Péptidos que tienen afinidad de unión por un anticuerpo que reconoce un epítopo en un bucle 2 de alfa 1 o bucle 1 de beta 2 de un receptor adrenérgico

Country Status (5)

Country Link
US (2) US8455442B2 (enExample)
EP (2) EP2080519A1 (enExample)
JP (1) JP5671347B2 (enExample)
ES (1) ES2639573T3 (enExample)
WO (1) WO2009090227A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2497828A1 (en) 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Use of aptamers in therapy and/or diagnosis of autoimmune diseases
US20140199318A1 (en) 2011-08-12 2014-07-17 Max-Del-Bruck-Centrum Fur Molekulare Medizin Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in alzheimer's and vascular dementia
KR20150032265A (ko) * 2012-06-26 2015-03-25 에프. 호프만-라 로슈 아게 세포 침투성 펩티드 및 세포 침투성 펩티드의 식별 방법
JP2017515799A (ja) * 2014-04-03 2017-06-15 オウ テルヴィスリク ピーマ バイオテウノロジーテ アレンダスケスクス コレステロール低下剤およびクロストリジウム・ディフィシレに対する抗微生物剤としてのラクトバチルス・プランタルムＩｎｄｕｃｉａ株ＤＳＭ２１３７９

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677968B2 (en) * 1992-09-25 1997-05-15 H. Lundbeck A/S DNA encoding human alpha 1 adrenergic receptors and uses thereof
JP2003514772A (ja) * 1999-09-21 2003-04-22 アフィーナ イミュンテヒニク ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｃｍを引き起こす自己抗体に対するペプチド
WO2002038592A2 (de) * 2000-11-08 2002-05-16 Affina Immuntechnik Gmbh Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
US6451547B1 (en) * 2001-04-25 2002-09-17 Syn X Pharma Process for differential diagnosis of Alzheimer's dementia and device therefor
US20020172676A1 (en) * 2001-05-16 2002-11-21 George Jackowski Method of treatment of alzheimer's disease and device therefor
WO2004051280A2 (de) * 2002-11-29 2004-06-17 Max-Delbrück-Centrum für Molekulare Medizin Bestimmung agonistischer autoantikörper
JP2008537961A (ja) * 2005-04-15 2008-10-02 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ Ｇｐｃｒモジュレーター
EP1832600A1 (en) * 2006-03-09 2007-09-12 Max-Delbrück-Centrum Für Molekulare Medizin Peptides against autoantibodies associated with glaucoma and use of these peptides
WO2008151847A1 (en) 2007-06-13 2008-12-18 Max-Delbrück-Centrum für Molekulare Medizin Autoantibody binding peptides and their use for the treatment of vascular diseases
WO2009132283A2 (en) * 2008-04-24 2009-10-29 University Of Miami Method for treating autoimmune disorders
US8216786B2 (en) * 2008-07-09 2012-07-10 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof

Also Published As

Publication number Publication date
US9574017B2 (en) 2017-02-21
US20110104226A1 (en) 2011-05-05
EP2244718A2 (en) 2010-11-03
US20130302292A1 (en) 2013-11-14
JP2011518113A (ja) 2011-06-23
EP2244718B1 (en) 2017-06-07
WO2009090227A2 (en) 2009-07-23
EP2080519A1 (en) 2009-07-22
JP5671347B2 (ja) 2015-02-18
US8455442B2 (en) 2013-06-04
WO2009090227A3 (en) 2010-02-04

Similar Documents

Publication Publication Date Title
ES2404940T3 (es) Reactivos de peptoide específicos para prión
CN103608456B (zh) 适体在自体免疫疾病的疗法和/或诊断中的用途
Baudier et al. The Zn2+ and Ca2+‐binding S100B and S100A1 proteins: beyond the myths
JP6955324B2 (ja) 医薬化合物を評価するための新規動物モデル
US20090220469A1 (en) Peptides against autoantibodies associated with glaucoma and use of these peptides
ES2639573T3 (es) Péptidos que tienen afinidad de unión por un anticuerpo que reconoce un epítopo en un bucle 2 de alfa 1 o bucle 1 de beta 2 de un receptor adrenérgico
JP2011057685A (ja) ニューロンの成長を調節する化合物およびそれらの使用
EA006230B1 (ru) ПЕПТИД, СПОСОБНЫЙ ОБРАЗОВЫВАТЬ СВЯЗИ С Ig1 И/ИЛИ Ig2 ДОМЕНАМИ АДГЕЗИОННОЙ МОЛЕКУЛЫ НЕРВНОЙ КЛЕТКИ, И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
CN102924585A (zh) 神经胚素变体
AU2003288434B2 (en) Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
AU2003209030B2 (en) Anti-infarction molecules
CN105745220A (zh) 结合β淀粉状蛋白的环状肽及其用途
US8796214B2 (en) Neurotrophic peptides
JP2001524826A (ja) 全身性紅斑性狼瘡を治療するためのペプチド
US20210371478A1 (en) Generation of brain and spinal cord neurons, cardiac myocytes, and hepatocytes using reg peptides, peptidomimetics, small molecules and stimulatory antibodies to reg receptor
US7749758B2 (en) Human and mammalian stem cell-derived neuron survival factors
US9708372B2 (en) Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer's and vascular dementia
US20090023662A1 (en) Identification of Agonistic Autoantibodies Associated with Humoral Kidney Rejection
JP6857854B2 (ja) サリューシン−β阻害剤のスクリーニング方法及びサリューシン−β阻害剤
JP2025516717A (ja) 血管新生を誘発する薬剤
JP2003512300A (ja) テネイシンｃによる軸索突起の伸長及び誘導
Saavedra et al. The discovery of a novel macrophage binding site
KR20130021673A (ko) Ｇｐｒ１７１ 단백질의 발현 또는 활성 억제제를 포함하는 암 치료 또는 암 전이 억제용 약학적 조성물
JP2011502975A (ja) ワクチンの準備のための本質不規則配列
JP2003274974A (ja) 薬物のスクリーニング方法